You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Amazon said that it will use its test for employees and other individuals who enter its facilities as part of its COVID-19 preparedness and response program.
The company also said that a previously granted EUA for its Alinity m SARS-CoV-2 assay has been expanded to include asymptomatic individuals and pooled testing.
Of the 32 companies in the index, 14 firms saw their stock prices increase, while 18 saw their share prices decline.
The firm said it is currently also developing Novodiag Resp-4, a molecular test for the rapid, on-demand detection of the viruses.
The firm said it intends to apply to obtain FDA Emergency Use Authorization and 510(k) clearance for a panel that detects respiratory targets in a single test.
The company has developed an analyzer to run PCR, immunochemistry, and cytometry tests at the same time for a variety of diseases including COVID-19.
The firm sells a rapid, point-of-care, PCR platform for infectious disease diagnostics, including SARS-CoV-2, influenza, respiratory syncytial virus, and strep A.
The PCR-based panel is designed to simultaneously detect SARS-CoV-2, influenza A and B, and respiratory syncytial virus, with results in less than two hours.
The firm is developing a test to determine interleukin-6 levels for SARS-CoV-2 patients and a rapid antigen test.
The test kit, which provides results in under two hours, is PCR system-agnostic and is suitable for use with a range of instruments, according to the company.